Sign in →

Test ID GBM Glomerular Basement Membrane Antibodies, IgG, Serum


Ordering Guidance


If patient is being evaluated for autoimmune skin disease, order CIFS / Cutaneous Immunofluorescence Antibodies (IgG), Serum for evaluation of anti-intercellular substance (ICS) and antibasement membrane zone (BMZ) antibodies.



Specimen Required


Container/Tube: 

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 0.5 mL


Forms

If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.

Secondary ID

8106

Useful For

Evaluating patients with rapid onset renal failure or pulmonary hemorrhage, as an aid in the diagnosis of Goodpasture syndrome

Method Name

Multiplex Flow Immunoassay

Reporting Name

Glomerular Basement Membrane IgG Ab

Specimen Type

Serum

Specimen Minimum Volume

0.35 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 21 days
  Frozen  21 days

Clinical Information

Antibodies to glomerular basement membrane (GBM) antigens cause glomerulonephritis, Goodpasture syndrome (glomerulonephritis, often with rapid onset renal failure, and pulmonary hemorrhage), and, less commonly, pulmonary hemosiderosis.(1) Nephrogenic GBM antigens are associated with the noncollagenous carboxyl extension of type IV procollagen. The immunologic stimuli that elicit production of GBM antibodies are not known. There is some evidence of a genetic association with HLA-DR2.

 

GBM antibody-mediated glomerulonephritis and Goodpasture syndrome occur with a bimodal age distribution primarily in males ages 20 to 40 and in patients older than age 50. Glomerulonephritis without pulmonary involvement is more common in the older age group, and shows a female predominance.

Reference Values

<1.0 U (negative)                     

≥1.0 U (positive)

Reference values apply to all ages.

Cautions

A positive test for glomerular basement membrane (GBM) antibodies cannot be relied upon exclusively to establish the diagnosis of a disease mediated by GBM antibodies. Weakly-positive test results may occur in other immune-mediated diseases, and renal or lung biopsy is often required to establish the diagnosis.

 

If patient is being evaluated for autoimmune skin disease, order CIFS / Cutaneous Immunofluorescence Antibodies (IgG), Serum for evaluation of anti-intercellular substance (ICS) and antibasement membrane zone (BMZ) antibodies.

Day(s) Performed

Monday through Friday

Report Available

Same day/1 to 3 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

83516

NY State Approved

Yes